We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study) (LIVING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02346487
Recruitment Status : Recruiting
First Posted : January 27, 2015
Last Update Posted : November 11, 2016
Sponsor:
Collaborators:
Information provided by (Responsible Party):

January 13, 2015
January 27, 2015
November 11, 2016
September 2015
December 2018   (Final data collection date for primary outcome measure)
Treatment effectiveness at 48 weeks based on a composite endpoint of: i) virologic response <1000 copies/ml ii) being alive and iii) on study drug [ Time Frame: 48 weeks ]
• Treatment effectiveness at 48 weeks based on a composite endpoint of: i) virologic response <1000 copies/ml ii) being alive and iii) on study drug
Same as current
Complete list of historical versions of study NCT02346487 on ClinicalTrials.gov Archive Site
  • Treatment effectiveness based on virologic, immunologic and clinical endpoints [ Time Frame: 96 weeks ]
    • Viral load suppression <1000 copies/ml (as well as <400 &<50 copies/ml where viral load can be measured on plasma) 48 weeks, 96 weeks, after treatment initiation among children under LPV/r based therapy (i.e. in completers) and at the end of the follow-up
    • Clinical failure at 48 weeks and at the end of follow-up defined as new or recurrent disease progression (WHO AIDS definition), death,
    • Immunologic failure as defined by the presence of any of the following:

      1. CD4 percentage fails to rise by 5 percentiles (or CD4 count fails to rise by at least 50 cells/mm3) during the first year of HAART.
      2. CD4 count drops by more than 50% of the peak achieved on HAART.
      3. Decline below age dependent CD4% or CD4 cells count/ml (WHO thresholds for severe immunodeficiency)
    • Retention on therapy
  • Rate of AEs/SAEs as measure of safety [ Time Frame: 96 weeks ]
    • Rate of severe adverse events
    • Rate of AE/serious AE leading to treatment discontinuation
    • Rate of targeted AEs for lopinavir/ritonavir as well as NRTIs (examples: GI side effects, liver toxicity, ABC-associated hypersensitivity reaction, ZDV-related anaemia and neutropenia…)
  • Pharmacokinetics - Plasma AUC [ Time Frame: 96 weeks ]
    • Plasma AUC, Tmax and C12/Cmin upon population PK modelling upon using sparse sampling
    • Exposure to LPV/r & adherence as measured by ARV levels in hair
  • Feasibility and acceptability questionnaires [ Time Frame: 96 weeks ]
    • Questionnaire on Acceptability by caregivers and children of the new LPV based formulation , in particular taste, ease of swallowing, ease of administration, adherence
  • Pharmacokinetics - Tmax [ Time Frame: 96 weeks ]
    • Plasma AUC, Tmax and C12/Cmin upon population PK modelling upon using sparse sampling
    • Exposure to LPV/r & adherence as measured by ARV levels in hair
  • Pharmacokinetics - C12/Cmin [ Time Frame: 96 weeks ]
    • Plasma AUC, Tmax and C12/Cmin upon population PK modelling upon using sparse sampling
    • Exposure to LPV/r & adherence as measured by ARV levels in hair
Same as current
Not Provided
Not Provided
 
Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)
Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally
The study will be carried out to provide supportive clinical data on the feasibility, efficacy, safety, and PK of LPV based therapies in routine treatment setting and will be based on the existing LPV/r pellets which already represent a clear advantage in comparison with the liquid formulation.

The primary objective is to evaluate the effectiveness of LPV/r pellets in addition to AZT/3TC (or ABC/3TC) paediatric fixed dose combination (FDCs) tablet under routine treatment conditions in HIV infected infants and young children who cannot swallow tablets.

As secondary objectives:

  • Document the safety of LPV/r pellets and AZT/3TC or ABC/3TC
  • Assess the population pharmacokinetics of LPV/r and NRTIs when administered as LPV/r pellets plus AZT/3TC or ABC/3TC
  • Measure adherence to the new formulation
  • Evaluate children acceptability of the LPV/r pellets and associated dual NRTIs as well as ease of use by the care giver.
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV
Drug: LPV/RTV pellets and AZT/3TC or ABC/3TC

Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:

  • Between 3 and 5.9kg: 2 capsules twice a day
  • Between 6 and 9.9kg: 3 capsules twice a day
  • Between 10 and 13.9kg: 4 capsules twice a day
  • Between 14 and 19.9kg: 5 capsules twice a day
  • Between 20 and 24.9kg: 6 capsules twice a day

Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:

  • Between 3 and 5.9kg: 1 tablet twice a day
  • Between 6 and 9.9kg: 1.5 tablets twice a day
  • Between 10 and 13.9kg: 2 tablets twice a day
  • Between 14 and 19.9kg: 2.5 tablets twice a day
  • Between 20 and 24.9kg: 3 tablets twice a day
Experimental: LPV/RTV pellets and AZT/3TC or ABC/3TC
Only 1 arm. No comparator
Intervention: Drug: LPV/RTV pellets and AZT/3TC or ABC/3TC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
3000
March 2019
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

• Past or current documentation of a confirmed diagnosis of HIV infection defined as two positive assays from two different samples taken at a different date as preferred option.

  • At any age: HIV-1 DNA PCR positivity
  • At any time >4 weeks of age: HIV-1 p24 antigen detection or HIV-1 RNA viral load > 5,000 copies/mL plasma
  • At any age >18 months: HIV-1 antibody reactive on two different manufacturers' licensed rapid tests based on a different antigen preparation and/or different test principal, or repeatedly reactive on a licensed enzyme immune assay (EIA)and confirmed on a second sample by any one of the following assays: rapid test (a third manufacturer), licensed EIA, Western blot, chemi-luminescence assay, or plasma RNA with a viral load > 5,000 copies/mL

One single positive PCR assay result will be acceptable for inclusion of a child less than 18 months in the study Although the 2nd PCR assay would not be performed at the time of treatment initiation/treatment switch,

  • In case the test is RNA PCR viral load), the sample should be taken before treatment initiation and analyzed as soon as possible thereafter,
  • In case the child is already on treatment, the test should be DNA PCR based, the blood sample can be taken while on treatment and the results be made available as soon as possible.
  • ARV treatment eligible children with LPV-based treatment indication* as defined by country-specific guidelines or the WHO pediatric treatment guidelines confirmed by investigator:

    1. ARV naïve, or
    2. Already on first line liquid lopinavir based treatment, or
    3. Failing first line NNRTI based therapy
  • Weight ≥3 and <25 kg at the time of enrolment.
  • Inability to swallow tablets*
  • Parent or legal guardian able and willing to provide written informed consent. *Age is not an inclusion criterion. Children older than 5 years who need a LPV/r based treatment and cannot swallow tablets are eligible. Analysis will be stratified according to study entry point (naïve, first line, failure)

Exclusion criteria

  • Planned or concurrent use of NNRTIs, integrase inhibitors, entry inhibitors, or PIs other than LPV/r.
  • PIs treatment failure with the presence or strong suspicion of a PI resistance mutation.
  • Clinical condition requiring the use of a prohibited medication in association with LPV/r
  • Any clinically significant disease or finding during screening that, in the investigator's opinion, would compromise participation in this study.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact: Francois Simon, MSc +41 22 907 77 25 fsimon@dndi.org
Contact: Olawale Salami, MD +254 020 3995024 osalami@dndi.org
Kenya,   Uganda
 
 
NCT02346487
DNDiHIVPed002
Yes
Not Provided
Not Provided
Drugs for Neglected Diseases
Drugs for Neglected Diseases
  • UNITAID
  • French Development Agency
Principal Investigator: Dalton Wamalwa, MD University of Nairobi, P.O Box 19676 00202 Nairobi
Drugs for Neglected Diseases
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP